M&A Synergies in Interviews: Cost vs Revenue, Timing, and Accretion Impact

Synergies are where M&A stories get sold and where bad deals hide. Interviewers ask about them to see whether you understand that "synergies" is not a magic EPS machine. There are types, timing, costs to achieve, and realization risk. If you can walk that cleanly, your accretion answers and deal discussions jump a level.

What a synergy is

A synergy is value created by combining two companies that neither had on a standalone basis: lower costs, higher revenue, or better capital efficiency.

In models, synergies usually show up as incremental EBITDA (or EBIT) in the combined forecast, after tax when you bridge to net income and EPS.

After-tax synergy ≈ Pre-tax synergy × (1 − t)
(before costs to achieve and PPA noise)

Cost synergies vs revenue synergies

Timing and costs to achieve

Synergies are not Day 1 cash.

How synergies change accretion

Accretion/dilution compares pro forma EPS to standalone EPS. Synergies increase combined earnings and push toward accretion. But:

• Costs to achieve reduce near-term earnings
• Higher purchase price / premium can offset synergy benefits
• Stock issuance dilution can overwhelm synergy contribution
• Step-up D&A can eat synergy gains on GAAP EPS

Strong interview habit: stack layers instead of stopping at "synergies make it accretive."

1. Financing mix (cash vs stock)
2. Premium / purchase multiple
3. Synergy ramp and costs to achieve
4. Purchase accounting

Diligence questions you should sound like you would ask

• What percent of synergies are cost vs revenue?
• What is the bridge by function (ops, procurement, G&A)?
• What is the historical hit rate on this buyer's prior deals?
• What systems work is required?
• Which synergies require customer consent or sales-cycle time?
• What retention risk exists if cuts go too deep?

Worked intuition example

Buyer standalone EPS $5.00.
Deal widens share count and adds interest such that without synergies, pro forma EPS is $4.70 (dilutive).
Pre-tax synergies $60M, tax 25% → +$45M NI.
On 100M pro forma shares that is +$0.45 EPS → pro forma about $5.15 (accretive), ignoring costs to achieve.

If Year 1 only realizes 40% of synergies and carries $20M after-tax costs to achieve, Year 1 may still be dilutive. Year 2 can flip. That Year 1 vs Year 2 distinction is a frequent Harborview-style teaching point.

Revenue synergy skepticism (sound senior)

Revenue synergies fail when:

• Customers overlap and churn rises after the deal
• Sales teams miss quotas during integration
• Pricing "power" alienates the base
• Channel conflict blocks cross-sell

A good line: "I underwrite cost synergies in the base case and treat revenue synergies as upside until diligence supports them."

Interview prompts and clean answers

"What kinds of synergies are there?"
"Primarily cost and revenue. Cost is usually more underwritable. Revenue needs evidence on attach rates and customer overlap. I also separate timing and costs to achieve from the run-rate number."

"How do synergies affect accretion?"
"They increase combined after-tax earnings, which helps EPS, but Year 1 can still look weak if integration costs hit early or only a fraction of run-rate is realized."

"Would you take management's synergy number at face value?"
"No. I want a functional bridge, timing, costs to achieve, and a track record check. Then I haircut in the base case."

Common mistakes

Practice

Build a merger case with a synergy toggle and a Year-1 ramp. Show EPS with zero synergies, 50% Year-1 realization, and full run-rate. Then explain the chart in 45 seconds. That is the interview skill: numbers plus skepticism.